MILabs Introduces New Benchtop Product Line

MILabs, B.V. the Netherlands‐based innovator and manufacturer of pre‐clinical SPECT/PET/CT imaging devices used in biomedical research, today announces the release of the new mini product family ‐ an easy‐to‐use series of benchtop SPECT and PET imagers for small animals that combine simplified workflow, compact dimensions and affordable pricing to bring high‐performance SPECT/PET within everyone’s reach.

MILabs’ mini is a new product family developed for researchers with limited lab space or research budgets, as solutions for high quality SPECT and/or PET imaging. The mini product family consists of three different platforms: the U‐SPECT mini, the U‐PET mini and the VECTor mini combining the best aspects from both SPECT and PET as well as advanced simultaneous SPECT/PET imaging, in a unique benchtop configuration. Moreover, even with these compact dimensions, the mini systems come with the same benefits that the world‐wide users of MILabs high‐performance U‐SPECT and VECTor systems get to enjoy: unmatched high resolution, list‐mode acquisitions, fast dynamic modes, high precision reconstruction algorithms and multi‐modality connectivity. In addition, the MILabs mini systems also offer streamlined workflow and user friendliness with simplified installation and attractive pricing, thereby effectively bridging the long‐existing gap between performance and price in preclinical imaging. A new history is written with the mini family by expanding the horizon of MILabs’ tradition in providing high‐end technologies with unmatchedperformance to include highly attractive pricing as an additional attribute.

About MILabs B.V.
MILabs provides high‐end pre‐clinical molecular imaging solutions (SPECT/PET/CT) for biomedical and pharmaceutical research. Today these systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as cancer, cardiac and neurodegenerative diseases, depression and diabetes.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.